-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Clovis Oncology announced today that its PARP inhibitor Rubraca (rucaparib) has achieved positive results in a Phase 3 clinical trial as first-line maintenance therapy
Ovarian cancer is the eighth leading cause of cancer death in women worldwide
Rubraca is an oral small molecule PARP1, 2, 3 inhibitor
In this randomized, double-blind, placebo-controlled Phase 3 clinical trial, patients with newly diagnosed ovarian cancer received Rubraca monotherapy or placebo after receiving first-line chemotherapy and achieving remission
Across all randomized patient populations, median PFS was 20.
In the HRD-positive subgroup of patients, Rubraca reduced the risk of disease progression or death by 53% (HR=0.
An exploratory endpoint was also assessed in a subgroup of HRD-negative patients, in which Rubraca reduced the risk of disease progression or death by 35% (HR=0.
References:
[1] Clovis Oncology's Rubraca® (Rucaparib) Significantly Improves Progression-Free Survival in First-line Maintenance Treatment in Women with Ovarian Cancer Regardless of Their Biomarker Status in Phase 3 ATHENA-MONO Trial.
